BRAF inhibitor alone was associated with a 5.2-fold increase in risk of cutaneous squamous-cell carcinoma (13.27% vs. 2.51%) and a higher risk keratoacanthoma (8.97% vs. 1.82%) than the combination of BRAF and MEK inhibitors. Here, MAP2K7 is linked to keratoacanthoma.